Mario Campone
0000-0002-5196-5908
Publication & Citation Trends
Publications
0 total
A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer
Cited by 2
Semantic Scholar
MCL-1 as a molecular switch between myofibroblastic and pro-angiogenic features of breast cancer-associated fibroblasts
Cited by 4
Semantic Scholar
EMT-ciliary signaling in quasi-mesenchymal-stem-like cells drives therapeutic resistance and is a druggable vulnerability in triple-negative breast cancer
Cited by 4
Semantic Scholar
Cancer associated fibroblasts mitigate the efficacy of the combination of chemotherapy and BCL-xL targeting in triple negative breast cancer cells OA
Cited by 0
Semantic Scholar
Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts OA
Cited by 13
Semantic Scholar
Primary cilia promote EMT-induced triple-negative breast tumor heterogeneity and resistance to therapy
Cited by 0
Semantic Scholar
NOXA/MCL-1 axis determines cell-death decision between apoptosis and pyroptosis and the inflammatory secretome of breast cancer cells treated with anti-mitotics OA
Cited by 1
Semantic Scholar
Research Topics
Advanced Breast Cancer Therapies
(330)
Cancer Treatment and Pharmacology
(268)
HER2/EGFR in Cancer Research
(248)
Breast Cancer Treatment Studies
(173)
Cancer Genomics and Diagnostics
(130)
Affiliations
Université Claude Bernard Lyon 1
Université Paris-Sud
Roche (Switzerland)
Hebron University
Novartis (Switzerland)